Acute Phase Biomarkers, Intensive Care (ICU), Sepsis
Conditions
Keywords
Monocyte Distribution, Monocyte-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, Acute Phase Reactans, Sepsis, Intensive Care Unit
Brief summary
The aim of this study is to investigate, in patients admitted to the intensive care unit either for reasons other than sepsis who subsequently develop sepsis or with a primary diagnosis of sepsis, whether monocyte distribution, monocyte-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio can be used in addition to conventional biomarkers, and to examine their relationships with these biomarkers.
Detailed description
For Group I (control group) patients, WBC, NLR, MLR, and monocyte distribution(MD) parameters obtained from the complete blood count on the day of their anesthesia outpatient clinic visit were used in the study. For Group II and Group III patients, on the day of sepsis diagnosis, lactate, CRP, PCT, WBC, NLR, MLR, and monocyte distribution(MD) values were recorded. For Groups II and III, SOFA and APACHE-II scores were calculated within the first 24 hours and documented. The day of sepsis diagnosis was defined as T0, and subsequent measurements of lactate, CRP, PCT, WBC, NLR, MLR, and monocyte distribution(MD) were recorded every 48 hours until sepsis resolution, discharge, or death, as T1, T2, T3, and T4, respectively. The monocyte distribution parameter is a research parameter within the complete blood count and does not have a defined reference laboratory range. In our study, statistical analysis of monocyte distribution(MD), MLR and NLR values from the control group was performed to determine a cut-off value.
Interventions
DIAGNOSTIC_TESTMonocyte Distribution
The monocyte distribution parameter is a research parameter within the complete blood count and does not have a defined reference laboratory range.
Sponsors
Oguz Gundogdu
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients monitored in the intensive care unit for at least 24 hours * Age over 18 years * Diagnosis of sepsis or septic shock
Exclusion criteria
* Patients with hematological diseases * Patients who have undergone organ or bone marrow transplantation * Patients diagnosed with AIDS * Patients receiving immunosuppressive therapy for any reason * Patients with chronic renal failure * Patients with liver failure not related to sepsis * Patients admitted due to intoxication * Patients with intracranial pathologies (e.g., mass, hemorrhage) that may lead to morbidity due to volume loading
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| WBC,NLR,MLR,MD,LACTATE,CRP,PCT | 15 days | For Group I (control group) patients WBC, NLR, MLR and monocyte distribution(MD) parameters obtained from the complete blood count on the day of their anesthesia outpatient clinic visit were used in the study. For Group II and Group III patients, on the day of sepsis diagnosis, lactate, CRP, PCT, WBC, NLR, MLR and monocyte distribution(MD) values were recorded. The day of sepsis diagnosis was defined as T0 and subsequent measurements of lactate, CRP, PCT, WBC, NLR, MLR, and MD were recorded every 48 hours until sepsis resolution, dischargevor death as T1, T2, T3, and T4, respectively. The monocyte distribution parameter is a research parameter within the complete blood count and does not have a defined reference laboratory range. In our study, statistical analysis of MD, MLR and NLR values from the control group was performed to determine a cut-off value. \[WBC 10\^3/mm3, CRP mg/L, PCT ng/mL,Lactate mmol/L, NLR 2-90(min-max), MLR 0.24-1.3(min-max), MD 8.9-13(min-max)\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SOFA and APACHE-II scores | Within the first 24 hours following the diagnosis of sepsis | For Groups II and III, SOFA and APACHE-II scores were calculated within the first 24 hours and documented. (SOFA score \>2, APACHE-II score between 0-71) |
Countries
Turkey (Türkiye)
Outcome results
None listed